Actelion nominates Garnier and Bertolin
This article was originally published in Scrip
In the latest round in the battle to control Actelion, the incumbent board has nominated industry veterans Jean-Pierre Garnier and Robert Bertolini for election to the company's board of directors at the 2011 annual general meeting of shareholders, to be held on 05 May 2011. If elected, Garnier, formerly CEO of GlaxoSmithKline, will become vice chairman of the board with a view to him taking over as chairman when Robert Cawthorne stands down at the 2012 AGM. Mr. Bertolini, is the former CFO of Schering-Plough, now part of Merck.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.